Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation

Journal of Surgical Research

Volumn 180, Issue 1, 2013, Pages

  Jin, Jian ^a   Wang, Liang ^a,b   Wang, Xiao Kai ^a,b   Lai, Ping Lin ^a   Huang, Min Jun ^a,b   Jin, Da Di ^a,b   Zhong, Zhao Ming ^a   Chen, Jian Ting ^a   Bai, Xiao Chun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Adipogenesis; Bone marrow fat; Osteoclast; Osteoprotegerin; Receptor activator of nuclear factor B ligand; Risedronate

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RISEDRONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SWITCHING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MICROENVIRONMENT; OSTEOCLASTOGENESIS; OSTEOPOROSIS; PRIORITY JOURNAL; WESTERN BLOTTING;

ADIPOGENESIS; BONE DENSITY CONSERVATION AGENTS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ETIDRONIC ACID; HUMANS; MESENCHYMAL STROMAL CELLS; MULTIPROTEIN COMPLEXES; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; TOR SERINE-THREONINE KINASES;

EID: 84873703718     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2012.03.018     Document Type: Article

References (39)

1. G. Duque Bone and fat connection in aging bone Curr Opin Rheumatol 20 2008 429
2. J.M. Gimble, S. Zvonic, and Z.E. Floyd Playing with bone and fat J Cell Biochem 98 2006 251
3. J.F. Griffith, D.K. Yeung, and G.E. Antonio Vertebral marrow fat content and diffusion and perfusion indexes in women with varying bone density: MR evaluation Radiology 241 2006 831
4. J. Justesen, K. Stenderup, and E.N. Ebbesen Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis Biogerontology 2 2001 165
5. P. Meunier, J. Aaron, and C. Edouard Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies Clin Orthop Relat Res 80 1971 147
6. W. Shen, J. Chen, and M. Punyanitya MRI-measured bone marrow adipose tissue is inversely related to DXA-measured bone mineral in Caucasian women Osteoporos Int 18 2007 641
7. A. Elbaz, X. Wu, and D. Rivas Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro J Cell Mol Med 14 2010 982
8. J.N. Beresford, J.H. Bennett, and C. Devlin Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures J Cell Sci 102 1992 341
9. Y.M. Lee, N. Fujikado, and H. Manaka IL-1 plays an important role in the bone metabolism under physiological conditions Int Immunol 22 2010 805
10. M. Hashizume, and M. Mihara The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis Arthritis 2011 2011 765624
11. T. Suda, N. Takahashi, and N. Udagawa Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families Endocr Rev 20 1999 345
12. H. Yasuda, N. Shima, and N. Nakagawa Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci U S A 95 1998 3597
13. M. Lamghari, L. Tavares, and N. Camboa Leptin effect on RANKL and OPG expression in MC3T3-E1 osteoblasts J Cell Biochem 98 2006 1123
14. X.H. Luo, L.J. Guo, and H. Xie Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway J Bone Miner Res 21 2006 1648
15. C.J. Rosen, C. Ackert-Bicknell, and J.P. Rodriguez Marrow fat and the bone microenvironment: Developmental, functional, and pathological implications Crit Rev Eukaryot Gene Expr 19 2009 109
16. H. Goto, M. Osaki, and T. Fukushima Human bone marrow adipocytes support dexamethasone-induced osteoclast differentiation and function through RANKL expression Biomed Res 32 2011 37
17. J.J. An, D.H. Han, and D.M. Kim Expression and regulation of osteoprotegerin in adipose tissue Yonsei Med J 48 2007 765
18. H.G. Bone, D. Hosking, and J.P. Devogelaer Ten years' experience with Alendronate for osteoporosis in postmenopausal women N Engl J Med 350 2004 1189
19. S.T. Harris, N.B. Watts, and H.K. Genant Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 1999 1344
20. J. Iwamoto, T. Takeda, and Y. Sato Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis - Usefulness of alendronate and risedronate Expert Opin Pharmacother 8 2007 2743
21. J.P. Walsh, L.C. Ward, and G.O. Stewart A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone Bone 34 2004 747
22. K. Wellington, and K.L. Goa Zoledronic acid: A review of its use in the management of bone metastases and hypercalcaemia of malignancy Drugs 63 2003 417
23. G. Wells, A. Cranney, and J. Peterson Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women Cochrane Database Syst Rev 1 2008 CD004523
24. H.B. Kwak, J.Y. Kim, and K.J. Kim Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss Biol Pharm Bull 32 2009 1193
25. H. Fujita, K. Kurokawa, and T. Ogino Effect of risedronate on osteoblast differentiation, expression of receptor activator of NF-κB ligand and apoptosis in mesenchymal stem cells Basic Clin Pharmacol Toxicol 109 2011 78
26. A.P. Carvalho, M.M. Bezerra, and V.C. Girão Anti-inflammatory and anti-nociceptive activity of risedronate in experimental pain models in rats and mice Clin Exp Pharmacol Physiol 33 2006 601
27. X. Bai, D. Ma, and A. Liu Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38 Science 318 2007 977
28. P.A. Kern, M. Saghizadeh, and J.M. Ong The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase J Clin Invest 95 1995 2111
29. J. Bassols, F.J. Ortega, and J.M. Moreno-Navarrete Study of the proinflammatory role of human differentiated omental adipocytes J Cell Biochem 107 2009 1107
30. S. Sengupta, T.R. Peterson, and D.M. Sabatini Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress Mol Cell 40 2010 310
31. X. Bai, and Y. Jiang Key factors in mTOR regulation Cell Mol Life Sci 67 2010 239
32. T.R. Peterson, S.S. Sengupta, and T.E. Harris mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway Cell 146 2011 408
33. J.E. Kim, and J. Chen Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis Diabetes 53 2004 2748
34. S. Kwan Tat, M. Padrines, and S. Théoleyre IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology Cytokine Growth Factor Rev 15 2004 49
35. M.R. McClung, P. Geusens, and P.D. Miller Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 2001 333
36. C. Roux, E. Seeman, and R. Eastell Efficacy of risedronate on clinical vertebral fractures within six months Curr Med Res Opin 20 2004 433
37. A. Cranney, J.D. Adachi, and G. Guyatt WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis Cochrane Database Syst Rev 1 2007 CD004523
38. G. Duque, W. Li, and M. Adams Effects of risedronate on bone marrow adipocytes in postmenopausal women Osteoporos Int 22 2011 1547
39. L. Fu, T. Tang, and Y. Miao Stimulation of osteogenic differentiation and inhibition of adipogenic differentiation in bone marrow stromal cells by alendronate via ERK and JNK activation Bone 43 2008 40